Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07078955
PHASE2

A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

Sponsor: BRIM Biotechnology Inc.

View on ClinicalTrials.gov

Summary

To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)

Official title: A Phase 2, Multicenter, Randomized, Open-Labeled, Artificial Tear-Controlled, 6-Week Clinical Study to Assess the Dose Regimen, Safety and Efficacy of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

99

Start Date

2025-12

Completion Date

2027-03

Last Updated

2025-10-20

Healthy Volunteers

No

Interventions

DRUG

BRM421 Ophthalmic Solution, 0.03%

A topical drop of 0.03% BRM421 ophthalmic solution.

DRUG

Artificial Tear

A topical drop of Artificial Tear.

DRUG

BRM421 Ophthalmic Solution, 0.06%

A topical drop of 0.06% BRM421 ophthalmic solution.

Locations (1)

New Taipei Municipal TuCheng Hospital

New Taipei City, Taiwan